Quantitative expression evaluation of PRAME gene in osteosarcoma

No abstract is available for this paper.

• Publication year

  2023

• Venue

  Molecular Biology Reports

• Publication date

  2023-03-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11033-023-08290-yPMID 36922454
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biological features of tissue and bone sarcomas investigated using an in vitro model of clonal selection.

  2020cited by this paper
• Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multiantigen-Associated Specific Cytotoxic T Lymphocytes: A Phase I Study.

  2019cited by this paper
• Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group

  2019cited by this paper
• Osteosarcoma.

  2016cited by this paper
• PRAME expression and promoter hypomethylation in epithelial ovarian cancer

  2016cited by this paper
• Computed tomography-guided percutaneous trephine removal of the nidus in osteoid osteoma patients: experience of a single center in Brazil*

  2015cited by this paper
• Expression and prognostic relevance of PRAME in primary osteosarcoma.

  2012cited by this paper
• Insights on PRAME and osteosarcoma by means of gene expression profiling

  2011cited by this paper
• PRAME gene expression profile in medulloblastoma.

  2011cited by this paper
• Immunotherapy Targets in Pediatric Cancer

  2011cited by this paper
• Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia

  2010cited by this paper
• PRAME expression and clinical outcome of breast cancer

  2008cited by this paper
• Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas

  2008cited by this paper
• Prevalence and prognostic and predictive relevance of PRAME in breast cancer

  2008cited by this paper
• Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival.

  2006cited by this paper
• A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer.

  2006cited by this paper
• The gene expression signatures of melanoma progression

  2005cited by this paper
• The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling.

  2005cited by this paper
• The Tumor-Associated Antigen PRAME Is Universally Expressed in High-Stage Neuroblastoma and Associated with Poor Outcome

  2004cited by this paper
• Use of plasma exchange in methotrexate removal in a patient with osteosarcoma and acute renal insufficiency

  2003cited by this paper
• Neoadjuvant chemotherapy for high‐grade central osteosarcoma of the extremity

  2003cited by this paper
• PRAME gene expression in childhood acute lymphoblastic leukemia.

  2002cited by this paper
• Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

  2002cited by this paper
• Osteosarcoma: clinical practice and the expanding role of biology.

  2002cited by this paper
• Osteosarcoma.

  1997cited by this paper
• Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor.

  1997cited by this paper
• Bone tumors, diagnosis, treatment, and prognosis

  1979cited by this paper
• Osteosarcoma of bone and its important recognizable varieties

  1977cited by this paper

• PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer

  2024cites this paper
• Preferentially Expressed Antigen in Melanoma Is a Multifaceted Cancer Testis Antigen with Diverse Roles as a Biomarker and Therapeutic Target

  2023cites this paper